Lokelma Full Prescribing Information, Dosage & Side Effects | MIMS Singapore
PDF) Sodium Zirconium Cyclosilicate
Safety Information | LOKELMA® (sodium zirconium cyclosilicate) 5g | 10g for oral suspension | For HCPs
Pharmacy Practice News Clinical JUNE 10, 2021 Potassium-Sparing Agents Put a Rise in RAASis By Gina Shaw Newer agents are reenergizing the treatment of hyperkalemia, a serious condition characterized by elevated serum potassium levels in patients ...
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia | American Society of Nephrology
Lokelma sodium zirconium cyclosilicate treatment for hyperkalaemia
The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure | BMC Nephrology | Full Text
Dosing and Administration for Dialysis and Non-Dialysis Patients | LOKELMA® (sodium zirconium cyclosilicate) 5g | 10g for oral suspension | For HCPs
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
Drug Trials Snapshots: LOKELMA | FDA
Dosing and Administration for Dialysis and Non-Dialysis Patients | LOKELMA® (sodium zirconium cyclosilicate) 5g | 10g for oral suspension | For HCPs
Lokelma Vs Kayexalate Which is More Effective? - Public Health
NDC 0310-1105 Lokelma Sodium Zirconium Cyclosilicate
Clinical Management of Hyperkalemia - Mayo Clinic Proceedings
PDF) The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia | American Society of Nephrology
FDA Approves a Label Update for Lokelma to Include Dosing Guidance for Treatment of Hyperkalemia in ESRD on Hemodialysis | Specialty Pharma Journal
NephMadness 2020: Hyperkalemia Region – AJKD Blog
Drug Trials Snapshots: LOKELMA | FDA
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia | American Society of Nephrology
These highlights do not include all the information needed to use LOKELMA® safely and effectively. See full prescribing information for LOKELMA®. LOKELMA® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018
These highlights do not include all the information needed to use LOKELMA® safely and effectively. See full prescribing information for LOKELMA®. LOKELMA® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018
PulmCrit - Sodium Zirconium Cyclosilicate for urgent treatment of hyperkalemia?
Lokelma Full Prescribing Information, Dosage & Side Effects | MIMS Hong Kong
JCM | Free Full-Text | Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis | HTML
